CARDIOGENIC SHOCK: Edited by Alexandre MebazaaVasopressor use in cardiogenic shockLevy, Brunoa,b,c; Klein, Thomasa,b,c; Kimmoun, Antoinea,b,cAuthor Information aService de Réanimation Médicale Brabois, CHRU Nancy, Pôle Cardio-Médico-Chirurgical bINSERM U1116, Faculté de Médecine, Vandoeuvre-les-Nancy cUniversité de Lorraine, Nancy, France Correspondence to Bruno Levy, Médecine Intensive et Reanimation Brabois, CHRU Nancy, Pôle Cardio-Médico-Chirurgical, 54511 Vandoeuvre-les-Nancy, France. Tel: +33 383154469; fax: +33 383154084; e-mail: email@example.com Current Opinion in Critical Care: August 2020 - Volume 26 - Issue 4 - p 411-416 doi: 10.1097/MCC.0000000000000743 Buy Metrics Abstract Purpose of review Data and interventional trials on vasopressor use during cardiogenic shock are scarce. Their use is limited by their side-effects and the lack of solid evidence regarding their effectiveness in improving outcomes. In the present article, we review the current use of vasopressor therapy during cardiogenic shock. Recent findings Two recent Cochrane analyses concluded that there was insufficient evidence to prove that any one vasopressor was superior to others in terms of mortality. A recent RCT and a meta-analysis on individual data suggested that norepinephrine may be preferred over epinephrine in patients with cardiogenic shock, in particular, after myocardial infarction. In patients with right ventricular failure and pulmonary hypertension, the use of vasopressin may be advocated under advanced monitoring. Summary When blood pressure needs to be restored, norepinephrine is a reasonable first-line agent. Information regarding comparative effective outcomes is sparse and their use should be limited to a temporary measure as a bridge to recovery, mechanical circulatory support or heart transplantation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.